The evidence that ablative therapy can cause tumor-specific immune responses was observed also in patients who underwent RFA, which can increase the number of tumor-associated antigen-derived peptides in peripheral blood [97], induce APCs activation and proliferation [98] and stimulate the secretion of Th1 cytokines (such as IL-2, TNF-α and IFN-γ) that promote CD8+ T activity [99]. This evidence concerns the gene IFNG and neoplasm.